Pharming Group (NASDAQ:PHAR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pharming Group (NASDAQ:PHAR) from a hold rating to a strong-buy rating in a research report report published on Sunday,Wall Street Zen reports.

Several other research analysts have also recently issued reports on PHAR. Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Wednesday, October 28th. Canaccord Genuity Group lifted their price target on shares of Pharming Group from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Tuesday, September 22nd. Weiss Ratings raised shares of Pharming Group from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, October 27th. Finally, Zacks Research upgraded shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, October 23rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $39.67.

Pharming Group Trading Up 1.6%

NASDAQ PHAR opened at $12.93 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.65 and a current ratio of 3.23. The firm has a market cap of $915.19 million, a price-to-earnings ratio of 40.41 and a beta of -0.05. The firm has a 50 day simple moving average of $10.76 and a 200-day simple moving average of $13.74. Pharming Group has a one year low of $9.11 and a one year high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.09. Pharming Group had a return on equity of 8.70% and a net margin of 6.23%. The company had revenue of $117.60 million for the quarter, compared to the consensus estimate of $117.60 million. Equities research analysts anticipate that Pharming Group will post 0.34 EPS for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP acquired a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group accounts for about 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent filing with the SEC. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.